MEA Ulcerative Colitis Market

MEA Ulcerative Colitis Market Size  (2024 to 2029)

As per the research report, the size of the Middle East and Africa Ulcerative Colitis Market is valued at USD 0.59 billion in 2024 and is projected to grow at a CAGR of 6.7%, to reach USD 0.81 billion by 2029 during the forecast period 2024 to 2029. 

Ulcerative Colitis is an inflammatory bowel disease that results in ulcers and inflammation of the rectum and colon. The disease usually lasts long term and the symptoms include diarrhea with blood and abdominal pain. It can also result in inflammations in several body parts and can also lead to colon cancer.

Growing prevalence for the early diagnosis among many individuals in order to have proper treatment procedures is a major factor fuelling the demand of the market in the Middle East and Africa. Ulcerative colitis is affecting many people from the past few years and is also one of the common factors for the market to grow tremendously. The rise in the demand to improve healthcare services in hospitals in many countries is leveling up the growth rate of the market. Focus on producing quality drugs in concern towards the people’s safety is additionally accelerating the growth rate of the ulcerative colitis market in the Middle East and Africa.

However, stringent rules and regulations by government bodies in order to approve new drugs are quietly impeding the growth rate of the market. People in a rural area are less aware of the availability of different treatment procedures for ulcerative colitis which is a challenging attribute for the market developers. Also, the expiration of patent rights for quality drugs is also an attribute hindering the growth rate of the market in the Middle East and Africa. The dearth of skilled persons in manufacturing drugs with the latest technologies especially in undeveloped countries is restricting the growth rate of the market.

The emergence of advanced technology in the field of biotechnology and the introduction of various treatment procedures for ulcerative colitis is to create growth opportunities for the market. In addition, a rise in the construction of hospitals and clinics with the latest equipment are propelling the growth rate of the market. Initiatives steps by the government to improve the needs for treatment procedures even in the rural areas are greatly influencing the demand of the ulcerative colitis market in the Middle East and Africa.

This research report segmented and sub-segmented into the following categories:

• By Product: Monoclonal Antibodies, Biosimilars, And Pharmaceuticals
• By Type: Proctosigmoiditis, Ulcerative Proctitis, Pancolitis, And Left-Sided Colitis
• By Route Of Administration: Oral And Injectable
• By Country:  KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA

Proctosigmoiditis is the most common type of ulcerative colitis and hence it holds the major market share.

Regionally, the Middle East and Africa is growing steadily from the past few years and is to have prominent shares in foreseen years. Saudi Arabia is leading with the highest shares of the market by owing to the launch of reimbursement schemes by the government in favor of the common people is lavishing the demand of this market. Rise in popularity through campaigns and digital advertisements are additionally fueling the growth rate of the ulcerative colitis market in this region. South Africa is next in holding prominent shares. Introducing quality drugs with the latest technology at effective prices is also an attribute boosting up the demand of the market in this country. Both government and non-government organizations are encouraging research institutes in the field of biologics which is enhancing the shares of the market.Middle East region lead the market due to the availability of better healthcare facilities. Due to the political unrest in both the regions, the market growth is slow and expansions become challenging.

The leading companies leading in the MEA Ulcerative Colitis Market profiled in the report are Abbott Laboratories, GlaxoSmithKline, Pfizer, Takeda Pharmaceuticals, AbbVie, Johnson and Johnson, Merck, Sanofi, F. Hoffmann-La Roche, and Shire Pharmaceuticals.